Startups
Neumirna Therapeutics
Neumirna Therapeutics is a Copenhagen-based biotechnology company developing RNA medicines for neurological disorders. Its platform targets microRNAs with antisense oligonucleotides to address disease mechanisms. Its lead program, NMT.001, focuses on drug-resistant epilepsy, with a further program in Parkinson's disease. Founded by neuroscience and RNA biology specialists, the company operates across Copenhagen, Basel and Boston.
Team
Andrea Grostøl DietzSenior Research Scientist |
 Andreas WallnöferIndependent Board Member · Chair of the R&D Committee |
Celia PalomoPhD Student |
Christian ChristensenOperations Officer |
Ellen DonnellyChief Executive Officer · Board Member |
Erika Procel OsunaStudent Assistant |
Ferenc TracikChief Medical Officer |
Franziska RichterScientific Advisory Board Member, Parkinson's Disease |
Georgina Sala GuaschResearch Associate |
Henrik KlitgaardScientific Co-Founder and Board Member · R&D Committee Member |
 Jacqueline FrenchScientific Advisory Board Member, Epilepsy |
Janine ErlerR&D Committee Member |
Jorge Santiago BajoStudent Assistant |
 Karl KieburtzScientific Advisory Board Member, Parkinson's Disease |
Lars Hellerung ChristiansenCo-Founder |
Lluís Riera-PonsatiDirector of Preclinical Development |
Luis ParerasChair of the Board of Directors |
Malthe ScharffPhD Student |
Manuel ToledoScientific Advisory Board Member, Epilepsy |
Milla KoistinahoBoard Member |
Paolo Di GiorgioBoard Member |
Pavel KleinScientific Advisory Board Member, Epilepsy |
Peter RasmussenChief Financial Officer |
Sakari KauppinenScientific Co-Founder |
Shideh MorovatiHead of Communications |
Tinna ReynisdóttirBioinformatician |
Ulrich GranzerR&D Committee Member |